From the Guidelines
Treatment of Chronic Ogilvie's Syndrome with Prucalopride
Prucalopride (Motegrity) should be used with caution for the treatment of chronic Ogilvie's syndrome due to limited evidence supporting its efficacy in this condition 1.
Key Considerations
- Dosing: If used, prucalopride should be started at a low dose of 1-2 mg once daily 1.
- Monitoring: Patients should be closely monitored for efficacy and potential adverse effects, such as abdominal pain and nausea 1.
- Alternative Options: Other treatment options, such as neostigmine or laxatives, may be preferred for chronic Ogilvie's syndrome due to the limited evidence supporting the use of prucalopride in this condition 1.
Important Points to Consider
- The use of prucalopride for chronic Ogilvie's syndrome is not well established, and its efficacy in this condition is uncertain 1.
- Prucalopride has prokinetic properties and is licensed for the treatment of chronic constipation in women when other laxatives have failed to provide an adequate response 1.
- The quality of evidence for prucalopride is limited, and its use in chronic Ogilvie's syndrome should be approached with caution 1.
From the Research
Prucalopride for Chronic Ogilvie's Syndrome
- There are no direct studies on the use of prucalopride (Motegrity) for chronic Ogilvie's syndrome in the provided evidence.
- However, prucalopride has been studied for its use in treating chronic idiopathic constipation, intestinal/colonic pseudo-obstruction, and post-operative ileus 2, 3, 4, 5, 6.
- Prucalopride has been shown to be effective in improving colonic motility, decreasing colonic transit time, and increasing complete spontaneous bowel movements in patients with chronic idiopathic constipation 2, 3, 4, 5.
- It has also been suggested that prucalopride may be helpful in the treatment of constipation caused by irritable bowel syndrome, spinal cord injury, opioid-induced constipation, and intestinal/colonic pseudo-obstruction 2.
- While there is no direct evidence on the use of prucalopride for chronic Ogilvie's syndrome, its mechanism of action and efficacy in similar conditions suggest that it may be a potential treatment option.
- Further studies would be needed to determine the safety and efficacy of prucalopride for chronic Ogilvie's syndrome.